Anthem Biosciences files revised Q1FY27 earnings presentation

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDF

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.5%1-day move

₹794.00

prior close

₹750.60

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.8+1.4-0.4+0.1-1.5-3.1-0.6———————

Up moveDown movePending

AI summary

Anthem Biosciences filed a revised Q1FY27 earnings presentation. Revenue fell 22.6% YoY to Rs 4,182 Mn due to delivery timing shifts. CRDMO down 24.7%, Specialty Ingredients down 11.5%. Despite revenue dip, EBITDA margins expanded 153 bps YoY to 39.6%, PAT margins rose to 27.1%, and PAT fell only 11.7% to Rs 1,199 Mn. Net cash grew to Rs 17,197 Mn. CEO said underlying demand stays strong with deliveries back-loaded to H2.

Likely market impact

Revenue decline flagged as timing-driven. Margin expansion and back-half pipeline are positives, though near-term weakness may pressure the stock.